Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 16/20 | 0.67 |
| ▸ | PGR | P06401 | 14/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4555748 | 0.99 | NR3C1 (0.65) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL292319 | 0.95 | NR3C1 (0.69) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL4558038 | 0.92 | NR3C1 (0.63) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL293515 | 0.89 | NR3C1 (0.73) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL292292 | 0.89 | NR3C1 (0.72) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL292075 | 0.88 | NR3C1 (0.71) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL291658 | 0.87 | NR3C1 (0.70) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL292257 | 0.87 | NR3C1 (0.70) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL14158607 | 0.84 | NR3C1 (0.65) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL290758 | 0.83 | NR3C1 (0.82) | NR3C1NR3C2PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | claimed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2056799-B1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2203160-B1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | BAUSCH & LOMB (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2190431-B1 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST FOR TREATING OR CONTROLLING ANTERIOR-SEGMENT INFLAMMATION | BAUSCH & LOMB (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2364707-B1 | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | BAUSCH & LOMB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | SOLTA MEDICAL IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | SOLTA MEDICAL, INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| CN-1158063-C | Rinse-off water-in-oil-in-water compositions | ˹��������ͼ˹�����µ� | 2004-07-21 | — | — | CN | disclosed |
| US-20030161796-A1 | Composition for treating hair | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-08-28 | — | — | US | disclosed |
| US-6022547-A | EXTERNAL AQUEOUS PHASE AND INTERNAL PHASE COMPRISING A PRIMARY WATER-IN-OIL EMULSION, WHEREIN THE PRIMARY EMULSION COMPRISES A FIRST TOPICALLY-ACTIVE COMPOUND, A SURFACTANT PHASE, OIL PHASE AND WATER | HELENE CURTIS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| US-5942216-A | COMPRISING AN EXTERNAL AQUEOUS PHASE OF A SURFACTANT CAPABLE OF FORMIG LIQUID CRYSTALS AS AN EMULSIFIER; THE INTERNAL WATER-IN OIL EMULSION HAVING A TOPICALLY-ACTIVE COMPOUND AND SURFACTANT AND OIL PHASES; HAIR AND SKIN TREATMENTS | HELENE CURTIS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| US-5656280-A | CONTAINING A SURFACTANT BLEND FOR STABILITY AND A TOPICALLY-ACTIVE COMPOUND | HELENE CURTIS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| CN-1138982-A | Rinse-off water-in-oil-in-water compositions | CURTIS HELENE IND INC (US) | 1997-01-01 | — | — | CN | disclosed |
| US-5589177-A | OIL SOLUBLE SILICONES WITH WATER FOR EMULSIONS FOR TOPICAL APPLICATION AND HAIR FIXATIVES | HELENE CURTIS, INC. (US) | 1996-12-31 | — | — | US | disclosed |
| EP-0717978-A2 | Rinse-off water-in-oil-in-water compositions | HELENE CURTIS INC. (US) | 1996-06-26 | — | — | EP | disclosed |
| EP-0715842-A2 | Water-in-oil-in-water compositions | HELENE CURTIS INC. (US) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 95/4885 |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | PTGIR, NR3C1, PTGDR | NR3C1 2/4885NR3C2 11/4885PGR 272/4885 |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | PTGIR, MC2R, NR3C1 | NR3C1 3/4885NR3C2 18/4885PGR 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.